Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bluejay Diagnostics, Inc. (BJDX)
USD1.36
+0.11 (+8.81%)
US NASDAQ Healthcare Medical - Devices
Address
360 Massachusetts Avenue 1720
Acton, MA, US
Acton, MA, US
CEO
Indranil Dey
Website
bluejaydx.com
IPO
2021-11-10
CIK 1704287 ISIN US0956336087
Description
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.36
+0.11 (+8.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.82
Float Shares
393.9K
Free Float %
86.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.70% | -1.10% | +1.70% | -32.96% | -71.13% | -32.96% | -75.28% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
1.36
DCF (Unlevered)
10.79
+693.2%
DCF (Levered)
11.23
+726.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-12.91
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+96.7% ★ Q1'26: +95.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%-735.8% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+879.4% Q1'26: +2,358.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.02×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
249.0K
est: 249.0K (+0.0%)
|
—
|
—
est: 5.05M (-100.0%)
|
7.86M
7.86M – 7.86M
+55.6% YoY
|
18.48M
18.48M – 18.48M
+135.0% YoY
|
32.65M
32.65M – 32.65M
+76.7% YoY
|
| EBITDA |
-9.01M
est: 149.4K (-6,131.7%)
|
-6.70M
|
-6.68M
est: 3.03M (-320.2%)
|
4.72M
4.72M – 4.72M
+55.6% YoY
|
11.09M
11.09M – 11.09M
+135.0% YoY
|
19.59M
19.59M – 19.59M
+76.7% YoY
|
| EBIT |
-9.32M
est: 149.4K (-6,336.8%)
|
-6.89M
|
-6.85M
est: 3.03M (-325.8%)
|
4.72M
4.72M – 4.72M
+55.6% YoY
|
11.09M
11.09M – 11.09M
+135.0% YoY
|
19.59M
19.59M – 19.59M
+76.7% YoY
|
| Net Income |
-9.30M
est: -440.14M (+97.9%)
|
-7.72M
est: -72.62M (+89.4%)
|
-6.85M
est: -229.91M (+97.0%)
|
-208.36M
-208.36M – -208.36M
+9.4% YoY
|
-14.37M
-14.37M – -14.37M
+93.1% YoY
|
179.62M
179.62M – 179.62M
+1,350.0% YoY
|
| SGA |
5.21M
est: 1.24M (+319.9%)
|
3.70M
|
3.91M
est: 25.21M (-84.5%)
|
39.21M
39.21M – 39.21M
+55.6% YoY
|
92.16M
92.16M – 92.16M
+135.0% YoY
|
162.85M
162.85M – 162.85M
+76.7% YoY
|
| EPS |
-292.88
est: -2,400.00 (+87.8%)
|
-456.76
est: -1,584.00 (+71.2%)
|
-15.25
est: -512.00 (+97.0%)
|
-464.00
-464.00 – -464.00
+9.4% YoY
|
-32.00
-32.00 – -32.00
+93.1% YoY
|
400.00
400.00 – 400.00
+1,350.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.46M
OE per share TTM
-14.22
Owner's Yield
-366.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3,249.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Indranil (Neil) Dey | 4.54M | 35.76% | 448.8K | 4.09M | 448.8K | 4.09M | IN | United States of America | 2021-12-22 | ↗ |
| 2 | Lana Management & Business Research International, LLC | 4.09M | 32.23% | — | 4.09M | — | 4.09M | OO | Massachusetts | 2021-12-22 | ↗ |
| 3 | Svetlana Dey | 4.09M | 32.23% | — | 4.09M | — | 4.09M | IN | United States | 2021-12-22 | ↗ |
| 4 | Douglas C. Wurth | 3.52M | 27.26% | 2.35M | 1.17M | 2.35M | 1.17M | IN | United States of America | 2021-12-22 | ↗ |
| 5 | Wurth Holdings, LLC | 1.17M | 9.23% | — | 1.17M | — | 1.17M | OO | Delaware | 2021-12-22 | ↗ |
| 6 | L1 Capital Global Opportunities Master Fund, Ltd. | 643.5K | 9.99% | 643.5K | — | — | — | FI | Cayman Islands | 2024-07-03 | ↗ |
| 7 | Amin Nathoo | 319.3K | 5.10% | — | 319.3K | — | 319.3K | HC, IN | Texas | 2024-11-14 | ↗ |
| 8 | Anson Advisors Inc. | 319.3K | 5.10% | — | 319.3K | — | 319.3K | FI, CO | Texas | 2024-11-14 | ↗ |
| 9 | Anson Funds Management LP | 319.3K | 5.10% | — | 319.3K | — | 319.3K | IA, PN | Texas | 2024-11-14 | ↗ |
| 10 | Anson Management GP LLC | 319.3K | 5.10% | — | 319.3K | — | 319.3K | HC, OO | Texas | 2024-11-14 | ↗ |
| 11 | Moez Kassam | 319.3K | 5.10% | — | 319.3K | — | 319.3K | HC, IN | Texas | 2024-11-14 | ↗ |
| 12 | Tony Moore | 319.3K | 5.10% | — | 319.3K | — | 319.3K | HC, IN | Texas | 2024-11-14 | ↗ |
| 13 | Armistice Capital, LLC | 194.5K | 9.99% | — | 194.5K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 14 | Steven Boyd | 194.5K | 9.99% | — | 194.5K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
1.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+1,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-13 | Dey Svetlana | Director | P-Purchase | A | Common Stock | 500 | 3.07 | 1.5K | 1,500 | — | ↗ |
| 2023-12-13 | Dey Indranil | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 3.27 | 1.6K | 28,526 | — | ↗ |
| 2023-09-26 | Scally Frances P | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-28 | Dey Indranil | Director / Officer | A-Award | A | Common Stock | 2,000 | 0.44 | 880.00 | 660,538 | — | ↗ |
| 2023-03-27 | Dey Indranil | Director / Officer | A-Award | A | Common Stock | 8,000 | 0.44 | 3.5K | 558,538 | — | ↗ |
| 2023-03-24 | Dey Svetlana | Director | A-Award | A | Common Stock | 10,000 | 0.44 | 4.4K | 47,500 | — | ↗ |
| 2023-03-07 | Cook Jason | Officer | — | D | Common Stock | 0 | 0.00 | — | 44,900 | — | ↗ |
| 2023-02-01 | ZEIDMAN FRED S | Director | A-Award | A | Common Stock | 27,500 | 0.44 | 12.1K | 27,500 | — | ↗ |
| 2023-02-01 | Wurth Douglas Clark | Director | A-Award | A | Common Stock | 27,500 | 0.44 | 12.1K | 2,313,849 | — | ↗ |
| 2023-02-01 | Gemignani Gary G | Director | A-Award | A | Common Stock | 27,500 | 0.44 | 12.1K | 27,500 | — | ↗ |
| 2023-02-01 | Fisher Kenneth R | Officer | F-InKind | D | Common Stock | 39,316 | 0.44 | 17.3K | 113,184 | — | ↗ |
| 2023-02-01 | Dey Svetlana | Director | A-Award | A | Common Stock | 27,500 | 0.44 | 12.1K | 37,500 | — | ↗ |
| 2023-02-01 | Dey Indranil | Director / Officer | F-InKind | D | Common Stock | 55,612 | 0.44 | 24.5K | 550,538 | — | ↗ |
| 2023-02-01 | CHASE DONALD R | Director | A-Award | A | Common Stock | 27,500 | 0.44 | 12.1K | 792,852 | — | ↗ |
| 2022-08-26 | Fisher Kenneth R | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 1.03 | 20.6K | 40,000 | — | ↗ |
| 2022-04-25 | Fisher Kenneth R | Officer | P-Purchase | A | Common Stock | 20,000 | 0.99 | 19.8K | 20,000 | — | ↗ |
| 2022-03-23 | Fisher Kenneth R | Officer | A-Award | A | Option (right to buy) | 65,000 | 1.31 | 85.2K | 65,000 | — | ↗ |
| 2022-03-22 | ZEIDMAN FRED S | Director | A-Award | A | Option to purchase common stock | 2,500 | 0.00 | — | 27,500 | — | ↗ |
| 2022-03-22 | Wurth Douglas Clark | Director | A-Award | A | Option to purchase common stock | 2,500 | 0.00 | — | 254,728 | — | ↗ |
| 2022-03-22 | Gemignani Gary G | Director | A-Award | A | Option to purchase common stock | 2,500 | 0.00 | — | 27,500 | — | ↗ |
| 2022-03-22 | Dey Svetlana | Director | A-Award | A | Option to purchase common stock | 2,500 | 0.00 | — | 27,500 | — | ↗ |
| 2022-03-22 | CHASE DONALD R | Director | A-Award | A | Option to purchase common stock | 2,500 | 0.00 | — | 113,262 | — | ↗ |
| 2022-03-17 | Wurth Douglas Clark | Director | P-Purchase | A | Common Stock | 40,000 | 1.18 | 47.1K | 2,286,349 | — | ↗ |
| 2022-03-17 | Kinder Gordon Winston | Officer | P-Purchase | A | Common Stock | 2,500 | 1.16 | 2.9K | 18,500 | — | ↗ |
| 2022-03-17 | Dey Svetlana | Director | P-Purchase | A | Common Stock | 10,000 | 1.18 | 11.8K | 10,000 | — | ↗ |
| 2022-03-16 | Wurth Douglas Clark | Director | P-Purchase | A | Common Stock | 60,000 | 1.09 | 65.4K | 2,246,349 | — | ↗ |
| 2022-03-14 | Kinder Gordon Winston | Officer | P-Purchase | A | Common Stock | 5,000 | 1.02 | 5.1K | 16,000 | — | ↗ |
| 2022-02-25 | Kinder Gordon Winston | Officer | A-Award | A | Option to purchase common stock | 8,066 | 1.09 | 8.8K | 48,066 | — | ↗ |
| 2022-02-25 | Dey Indranil | Director / Officer / 10% Owner | A-Award | A | Option to purchase common stock | 14,116 | 1.09 | 15.4K | 15,848 | — | ↗ |
| 2022-01-10 | ZEIDMAN FRED S | Director | A-Award | A | Option to purchase common stock | 15,000 | 2.79 | 41.9K | 25,000 | — | ↗ |
| 2022-01-10 | Wurth Douglas Clark | Director / 10% Owner | A-Award | A | Option to purchase common stock | 25,000 | 2.79 | 69.8K | 252,228 | — | ↗ |
| 2022-01-10 | Dey Svetlana | Director / 10% Owner | A-Award | A | Option to purchase common stock | 25,000 | 2.79 | 69.8K | 25,000 | — | ↗ |
| 2022-01-10 | CHASE DONALD R | Director | A-Award | A | Option to purchase common stock | 25,000 | 2.79 | 69.8K | 110,762 | — | ↗ |
| 2021-12-15 | Gemignani Gary G | Director | A-Award | A | Option to purchase common stock | 25,000 | 2.72 | 68.0K | 25,000 | — | ↗ |
| 2021-11-13 | Gemignani Gary G | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-09 | Wurth Douglas Clark | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,108,883 | — | ↗ |
| 2021-11-09 | Dey Svetlana | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,091,356 | — | ↗ |
| 2021-11-09 | Dey Indranil | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,091,356 | — | ↗ |
| 2021-11-09 | CHASE DONALD R | Director | — | D | Common Stock | 0 | 0.00 | — | 765,352 | — | ↗ |
| 2021-07-02 | ZEIDMAN FRED S | Director | — | D | Option (right to buy) | 10,000 | 3.50 | 35.0K | 0 | — | ↗ |
| 2021-07-02 | Kinder Gordon Winston | Officer | — | D | Option (right to buy) | 40,000 | 3.50 | 140.0K | 0 | — | ↗ |
| 2020-07-24 | Dey Indranil | Director / Officer / 10% Owner | — | D | Warrant (right to buy) | 945 | 2.30 | 2.2K | 0 | — | ↗ |
| 2020-07-22 | Wurth Douglas Clark | Director / 10% Owner | — | I | Warrant (right to buy) | 7,868 | 0.95 | 7.5K | 0 | — | ↗ |
| 2020-07-22 | Dey Indranil | Director / Officer / 10% Owner | — | D | Warrant (right to buy) | 787 | 0.95 | 747.65 | 0 | — | ↗ |
| 2019-04-05 | Wurth Douglas Clark | Director / 10% Owner | — | I | Warrant (right to buy) | 62,000 | 2.30 | 142.6K | 0 | — | ↗ |
| 2019-04-05 | CHASE DONALD R | Director | — | D | Warrant (right to buy) | 22,818 | 2.30 | 52.5K | 0 | — | ↗ |
| 2019-02-23 | CHASE DONALD R | Director | — | D | Option (right to buy) | 10,490 | 0.95 | 10.0K | 0 | — | ↗ |
| 2018-12-27 | Wurth Douglas Clark | Director / 10% Owner | — | D | Option (right to buy) | 118,020 | 0.95 | 112.1K | 0 | — | ↗ |
| 2018-10-11 | Wurth Douglas Clark | Director / 10% Owner | — | D | Option (right to buy) | 39,340 | 0.16 | 6.3K | 0 | — | ↗ |
| 2018-10-11 | CHASE DONALD R | Director | — | D | Option (right to buy) | 39,340 | 0.16 | 6.3K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
453.5K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Neil Dey President & Chief Executive Officer | 328.2K | — | — | — | 137.5K | 7.9K | 473.6K | 0.00% | ↗ |
| 2 | 2025 | Jason Cook Chief Technology Officer | 111.6K | — | — | — | — | 214.6K | 326.2K | 0.00% | ↗ |
| 3 | 2024 | Neil Dey President & Chief Executive Officer | 283.8K | — | — | — | — | 7.1K | 290.9K | 0.00% | ↗ |
| 4 | 2024 | Jason Cook Chief Technology Officer | 241.8K | — | — | — | — | 9.3K | 251.1K | 0.00% | ↗ |
| 5 | 2023 | Kenneth Fisher Chief Financial Officer | 232.1K | 64.6K | — | — | — | 98.9K | 395.3K | 0.00% | ↗ |
| 6 | 2023 | Neil Dey President & Chief Executive Officer | 285.0K | — | — | — | — | 7.1K | 292.2K | 0.00% | ↗ |
| 7 | 2023 | Jason Cook Chief Technology Officer | 233.8K | — | — | — | — | 6.6K | 240.3K | 0.00% | ↗ |
| 8 | 2022 | Neil Dey President & Chief Executive Officer | 337.4K | 70.0K | — | 12.3K | — | 5.7K | 425.4K | 2.89% | ↗ |
| 9 | 2022 | Kenneth Fisher Chief Financial Officer | 204.1K | 99.0K | — | 67.6K | — | 3.4K | 374.2K | 18.07% | ↗ |
| 10 | 2022 | Kenneth Fisher Chief Financial Office | 204.1K | 99.0K | — | 67.6K | — | 3.4K | 374.2K | 18.07% | ↗ |
| 11 | 2022 | Jason Cook Chief Technology Officer | 212.1K | 60.7K | — | 4.6K | — | 5.6K | 283.1K | 1.64% | ↗ |
| 12 | 2021 | Jason Cook Chief Technology Officer | 100.8K | 16.6K | — | 46.3K | — | 90.0K | 253.7K | 18.23% | ↗ |
| 13 | 2021 | Gordon Kinder Former Chief Financial Officer | 118.3K | 25.2K | — | 26.8K | — | 23.3K | 193.6K | 13.84% | ↗ |
| 14 | 2021 | Neil Dey President & Chief Executive Officer | 137.5K | 44.1K | — | — | — | — | 181.6K | 0.00% | ↗ |
| 15 | 2020 | Neil Dey President & Chief Executive Officer | 20.8K | — | — | — | — | — | 20.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Indranil Dey | Principal Financial, Accounting & Executive Officer, President, Chief Executive Officer and Director | 473.6K | male |
| Kevin Vance | Chief Commercial Officer | — | male |
| Mark W. Feinberg | Chief Medical Advisor | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BJDX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
